Skip to content

Berberine

Berberine is a plant alkaloid known for its potential to improve metabolic health by activating AMP-activated protein kinase (AMPK), which plays a key role in regulating glucose and lipid metabolism. It is often used as a natural alternative to metformin for managing blood sugar levels and may support longevity by improving metabolic markers.

Intelligence Profile

Research Papers

Key Research Papers and Clinical Trials

The research literature on berberine spans several therapeutic areas, though many studies are still ongoing or recently completed without published results.

Clinical Trials

Several clinical trials have investigated berberine's effects on metabolic conditions. A completed randomized controlled trial (NCT03388762) examined a polyherbal dietary supplement containing berberine for prediabetes, though specific results are not yet available. Another completed study (NCT04428606) evaluated synbiotics in pre-diabetic patients, which may have included berberine components.

Currently, researchers are conducting a Phase 2/3 trial (NCT06782646) specifically examining berberine's sex-specific effects on lipids and lipoproteins, suggesting interest in its cardiovascular benefits. A Phase 3 trial (NCT04860063) is investigating berberine's safety and efficacy for metabolic syndrome in people living with HIV receiving antiretroviral therapy, though the current status is unknown.

Research Papers

Recent systematic reviews and meta-analyses have examined berberine in clinical contexts. One 2026 meta-analysis (PMID: 42433212) specifically evaluated adjunctive berberine for schizophrenia patients with metabolic syndrome, indicating growing interest in addressing antipsychotic-induced metabolic complications.

The research also encompasses broader applications, with studies examining berberine as part of combination therapies. These include investigations into natural compounds for allergic diseases (PMID: 42437846), cardiovascular protection against drug-induced toxicity (PMID: 42431648), and wound healing applications using berberine-loaded hydrogels (PMID: 42424602).

Additional research has explored berberine's role in integrative oncology approaches for colorectal cancer (PMID: 42434742) and its microbiota-mediated effects on atherosclerosis through metabolic and inflammatory pathways (PMID: 42434299).

Note: This synthesis is based on available trial registrations and publication titles. Detailed study results, sample sizes, and specific outcomes are not provided in the source material. Readers should consult full published papers and speak with healthcare providers before making treatment decisions.

Free account required

Research papers requires a free AXIFI account to access clinical data, safety profiles, and research papers.